According to the report titled ‘GLOBAL Liquid Biopsy Market 2021-2028’, available with Market Study Report, global liquid biopsy market is anticipated to register a compound annual growth rate of 18.54% during 2021-2028.
 

Higher susceptibility to cancer in aged population due to frail immunity, a steady increase in the cases of breast cancer and colorectal cancer, coupled with government initiatives for cognizance of early disease diagnosis are the factors propelling the growth of global liquid biopsy market during the study period.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3754634/
 

Also, technological advancements, and establishment of diagnostic centers are adding to the demand for liquid biopsy.
 

On the downside, lack of reimbursement for liquid biopsy procedure, scarcity of skilled professionals, higher costs are the restraints affecting the market outlook.
 

In terms of therapeutic application, global liquid biopsy market is divided into lung cancer, breast cancer, prostate cancer, colorectal cancer, melanoma cancer, and other non-oncology applications. While clinical applications include diagnosis & screening, treatment selection, prognosis & reoccurrence monitoring, and treatment monitoring.
 

Speaking of biomarker type, nucleic acid, protein, extracellular vesicles, and cells are the various market segments. As per analysis platform, the marketplace is categorized into NGS, microarray, PCR, proteomics, and others.
 

Based on analysis purpose, worldwide liquid biopsy industry is segmented into early detection/screening, therapy guidance, monitoring, and diagnosis. Moving on to product ambit, the report includes circulating tumor DNA, circulating tumor cells, cell-free DNA, and extracellular vesicles. Whereas, different end-user verticals are hospitals, clinical diagnostic laboratories, and physician’s office laboratories.
 

Geographically, Asia-Pacific is anticipated to lead global liquid biopsy market forecast through 2028, credited to dense population in countries like India and China, in consort with soaring medical expenditure, and improve patient awareness about medical diagnostics & treatments.
 

Moving on to competitive landscape, Qiagen N.V., Menarini Silicon Biosystems Inc., Illumina Inc., Biocept Inc., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Guardant Health Inc., Foundation Medicine Inc., MDxHealth, Agilent Technologies Inc., Thermo Fisher Scientific, GRAIL Inc., Adaptive Biotechnologies, ANGLE plc, Becton Dickinson and Company (BD), F. Hoffmann-La Roche AG, and Natera Inc. are catering to the global liquid biopsy market.